TY - JOUR
T1 - Feasibility and perioperative outcomes of robotic-assisted surgery in the management of recurrent ovarian cancer
T2 - A multi-institutional study
AU - Escobar, Pedro F.
AU - Levinson, Kimberly L.
AU - Magrina, Javier
AU - Martino, Martin A.
AU - Barakat, Richard R.
AU - Fader, Amanda N.
AU - Leitao, Mario M.
PY - 2014/8
Y1 - 2014/8
N2 - Objectives Minimally invasive surgery for recurrent ovarian cancer is generally not performed. The aim of this study was to assess the feasibility and surgical outcomes of robotic-assisted surgery in the management of recurrent ovarian cancer. Methods Eligible patients included those with confirmed recurrent ovarian cancer amenable to surgical resection and in which a complete resection was thought to be feasible with the use of the robotic platform. Patients with evidence of carcinomatosis were not considered for a robotic approach. Clinical and pathologic data were abstracted from the medical records. Appropriate statistical tests were performed using SPSS statistical software program (SPSS 20.0 Inc., Chicago, IL). Results A total of 48 patients were identified. Thirty-six (75%) patients had a recurrent mass or masses isolated to one anatomic region (pelvis or abdomen). Conversion to laparotomy was necessary in 4 (8.3%) cases. In cases not requiring conversion to laparotomy, the median operative time, EBL, and length of stay were 179.5 min, 50 cc, and 1 day, respectively. An optimal debulking was achieved in 36 (82%) cases. Complications occurred in 6 (13.6%) cases. The median operative time, EBL, length of stay, and complications were all statistically significantly lower in the cases not converted to laparotomy compared to those that were (p < 0.001). Conclusions This study suggests that select patients with recurrent ovarian cancer in the absence of carcinomatosis may be candidates for secondary surgical cytoreduction via a robotic approach. Surgical and postoperative outcomes appear to be favorable compared to reports of laparotomy in recurrent ovarian cancer.
AB - Objectives Minimally invasive surgery for recurrent ovarian cancer is generally not performed. The aim of this study was to assess the feasibility and surgical outcomes of robotic-assisted surgery in the management of recurrent ovarian cancer. Methods Eligible patients included those with confirmed recurrent ovarian cancer amenable to surgical resection and in which a complete resection was thought to be feasible with the use of the robotic platform. Patients with evidence of carcinomatosis were not considered for a robotic approach. Clinical and pathologic data were abstracted from the medical records. Appropriate statistical tests were performed using SPSS statistical software program (SPSS 20.0 Inc., Chicago, IL). Results A total of 48 patients were identified. Thirty-six (75%) patients had a recurrent mass or masses isolated to one anatomic region (pelvis or abdomen). Conversion to laparotomy was necessary in 4 (8.3%) cases. In cases not requiring conversion to laparotomy, the median operative time, EBL, and length of stay were 179.5 min, 50 cc, and 1 day, respectively. An optimal debulking was achieved in 36 (82%) cases. Complications occurred in 6 (13.6%) cases. The median operative time, EBL, length of stay, and complications were all statistically significantly lower in the cases not converted to laparotomy compared to those that were (p < 0.001). Conclusions This study suggests that select patients with recurrent ovarian cancer in the absence of carcinomatosis may be candidates for secondary surgical cytoreduction via a robotic approach. Surgical and postoperative outcomes appear to be favorable compared to reports of laparotomy in recurrent ovarian cancer.
KW - Minimally invasive surgery
KW - Robotic surgery
KW - Surgical technique
UR - http://www.scopus.com/inward/record.url?scp=84905565122&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84905565122&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2014.05.007
DO - 10.1016/j.ygyno.2014.05.007
M3 - Article
C2 - 24844594
AN - SCOPUS:84905565122
SN - 0090-8258
VL - 134
SP - 253
EP - 256
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 2
ER -